[HTML][HTML] Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune …

RS Patel, B Agrawal - Frontiers in Immunology, 2023 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, has infected> 600 million people in the ongoing global pandemic. Several …

[HTML][HTML] Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune …

RS Patel, B Agrawal - Frontiers in Immunology, 2023 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, has infected> 600 million people in the ongoing global pandemic. Several …

[PDF][PDF] Raj S. Patel and Babita Agrawal

M Tagliamonte, E Andreano, E De Gaspari, B Agrawal - 2023 - scienceopen.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, has infected more than 650 million people and caused more than 6.6 million …

Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune …

RS Patel, B Agrawal - Frontiers in Immunology, 2023 - europepmc.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, has infected> 600 million people in the ongoing global pandemic. Several …

Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune …

RS Patel, B Agrawal - Frontiers in immunology, 2023 - pubmed.ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
COVID-19, has infected> 600 million people in the ongoing global pandemic. Several …